Alkermes plc is a fully integrated, global biopharmaceutical company focused on developing innovative medicines that address the unmet needs and challenges of people living with serious, chronic diseases. At Alkermes plc, our employees consistently strive to provide physicians and patients with better treatment options. Through our scientific expertise, proprietary technologies and global resources, we are uniquely positioned to continue building a portfolio of medicines for major clinical conditions with a focus on central nervous system (CNS) disorders. Our success to date is evident from our more than 20 marketed drugs, including breakthrough treatments in major diseases, such as schizophrenia, addiction, diabetes and multiple sclerosis. Beyond our commercial products, we have a promising pipeline of proprietary drug candidates, many in late-stage development. Both our commercialized products and rich pipeline demonstrate our leadership in drug development for CNS diseases, a therapeutic area where we have established expertise and a promise for delivering new treatments. KEY COMMERCIAL PRODUCTS WEBSITE www.alkermes.com TICKER SYMBOL NASDAQ: ALKS HEADQUARTERS Connaught House 1 Burlington Road Dublin 4, Ireland +353 1 772 8000 EMPLOYEES Approximately 1,250 WW CONTACTS Rebecca Peterson Senior Vice President, Corporate Communications Voice: +1 781 609 6378 Blair Jackson Vice President, Business Development Voice: +1 781 609 6594 Our diverse portfolio of more than 20 commercial products reflects our years of experience in developing innovative and patient-inspired solutions. Among these, five key commercial products are the drivers to propel our growth. AMPYRA® (dalfampridine) is a twice-daily, controlled-release tablet indicated as a treatment to improve walking in patients with multiple sclerosis. AMPYRA is approved in the U.S. where it is marketed by Acorda Therapeutics, Inc. Biogen Idec holds the rights to develop and commercialize the medication in all markets outside the U.S., where it is sold under the trade name FAMPYRA®. BYDUREON® (exenatide extended-release for injectable suspension) is the first and only once-weekly therapy for the treatment of type 2 diabetes. BYDUREON is an extendedrelease injectable suspension of exenatide – the same active ingredient in BYETTA®. BYDUREON is marketed in the U.S. and EU by AstraZeneca. INVEGA® SUSTENNA® (paliperidone palmitate) is a once-monthly injectable form of paliperidone (INVEGA®) indicated for the treatment of schizophrenia. Janssen Pharmaceuticals, Inc. markets INVEGA SUSTENNA, which is commercialized under the trade name XEPLION® in the EU. RISPERDAL® CONSTA® (risperidone LongActing Injection) is a long-acting injectable form of Janssen’s schizophrenia drug RISPERDAL® (risperidone). It is administered once every two weeks, rather than daily, for the management of schizophrenia and bipolar I disorder. RISPERDAL CONSTA is commercialized by Janssen in more than 90 countries, including the U.S., the UK, Japan and Germany. VIVITROL® (naltrexone for extended-release injectable suspension) is an extended-release injectable formulation of naltrexone. It is the first and only non-narcotic, non-addictive, oncemonthly medication for both alcohol and opioid dependence. Designed for once-monthly dosing, VIVITROL eliminates the need for patients to make a daily decision about taking their medicine. Alkermes commercializes VIVITROL in the U.S. Janssen Pharmaceuticals is responsible for the commercialization of VIVITROL in Russia and the CIS. CLINICAL DEVELOPMENT PROGRAMS At Alkermes plc, we approach the development of new therapeutics with a thoughtful focus on patients’ real-world needs. We are committed to providing patients and caregivers with medicines that offer benefits in terms of safety, efficacy and ultimately, improved health outcomes. This is illustrated by our focused and growing proprietary and partnered pipeline. Preclinical CANDIDATE Phase 1 Phase 2 Phase 3 FDA Review Aripiprazole Lauroxil (Schizophrenia) INVEGA SUSTENNA 3-month (Schizophrenia) Exenatide Once Weekly Suspension (Type 2 Diabetes) ALKS 5461 (Major Depressive Disorder) Exenatide Once Monthly (Type 2 Diabetes) ALKS 3831 (Schizophrenia) ALKS 8700 (Multiple Sclerosis) ALKS 7106 (Pain) RDB 1419 (Cancer) LEADERSHIP TEAM GLOBAL PRESENCE RICHARD F. POPS Chairman and Chief Executive Officer SHANE COOKE President KATHRYN L. BIBERSTEIN Senior Vice President, Chief Legal Officer and Chief Compliance Officer, and Secretary Alkermes plc MADELINE D. COFFIN Vice President, Human Resources ELLIOT W. EHRICH, M.D. Senior Vice President, Research and Development, and Chief Medical Officer JAMES M. FRATES Alkermes Corporate Headquarters Connaught House 1 Burlington Road Dublin 4, Ireland +353 1 772 8000 Athlone, Ireland Facility Monksland, Athlone Co Westmeath, Ireland +353 90 649 5000 Gainesville, Georgia Facility 1300 Gould Drive Gainesville, GA 30504 +1 770 531 8100 Wilmington, Ohio Facility 265 Olinger Circle Wilmington, OH 45177 +1 937 382 5642 Waltham, Massachusetts Facility 852 Winter Street Waltham, MA 02451 +1 781 609 6000 Senior Vice President, Chief Financial Officer GEORGIANNA HARRIS, Ph.D. Vice President, Regulatory Affairs BLAIR C. JACKSON Vice President, Business Development MICHAEL J. LANDINE Senior Vice President, Corporate Development PETER NORMAN Vice President, Government Policy and Affairs REBECCA J. PETERSON Senior Vice President, Corporate Communications GORDON G. PUGH Senior Vice President, Chief Operating Officer and Chief Risk Officer SRDJAN STANKOVIC, M.D. Senior Vice President, Clinical Development and Medical Affairs MARK P. STEJBACH Senior Vice President, Chief Commercial Officer AMPYRA® and FAMPYRA® are registered trademarks of Acorda Therapeutics, Inc. BYDUREON® and BYETTA® are registered trademarks of Amylin Pharmaceuticals, LLC and AstraZeneca Pharmaceuticals LP. RISPERDAL®, RISPERDAL® CONSTA®, INVEGA® and INVEGA® SUSTENNA® are registered trademarks of Janssen Pharmaceuticals, Inc. XEPLION® is a registered trademark of Johnson & Johnson Corporation. VIVITROL® is a registered trademark of Alkermes, Inc. Rev: Aug 2014
© Copyright 2024 ExpyDoc